

Astellas Transfers Three Products in Asia Region to Daiichi Sankyo

TOKYO, October 15, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that subsidiaries of Astellas will transfer their marketing authorizations, trademark, and related contracts for “Nasea (5HT₃ receptor antagonist-type antiemetic)”, “Perdipine (calcium channel blocker)”, and “Oldeca (sustained release calcium antagonist)” (the “Products”) in Korea, Thailand, the Philippines, Indonesia, China and Taiwan to Daiichi Sankyo Co., Ltd. under an Asset Purchase Agreement concluded between both parties. Closing of the agreement is scheduled in third quarter of the fiscal year 2019.

After closing of the agreement, Astellas will work closely with Daiichi Sankyo to ensure smooth transfer of the Products to continue stable delivery to patients.

Marketing authorization of the Products in Japan, supply business of active ingredients/bulk to third parties in and outside of Japan, as well as the royalty business in Japan has been previously transferred to LTL Pharma Co., Ltd., under the Asset Purchase Agreement in 2017.

(1) Purpose of Asset Purchase Agreement

The agreement is a part of Astellas’ ongoing efforts to improve the quality and efficiency of operations and to optimize its cost structure so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will further expand our business in Asia region through optimization of resource allocation.

(2) Financial terms of Asset Purchase Agreement

¥ 9.6 billion

(3) Schedule of Asset Purchase Agreement

July 31, 2019: Conclusion of the Asset Purchase Agreement

Third quarter of the fiscal year 2019: Closing of the Asset Purchase Agreement
(tentative)

After closing of the agreement, marketing authorization of the Products will be transferred in each country. Closing of the agreement shall be subject to fulfillment of

the conditions, including obtaining the approval and permission from authorities in each country.

(4) List of the Products

Products Name (Generic Name)	Formulation	Therapeutic Category	Target Country
Nasea (ramosetron hydrochloride)	injection, OD tablets	5HT ₃ receptor antagonist-type antiemetic	Korea, Thailand, Philippines and Indonesia
Perdipine (nicardipine hydrochloride)	injection	calcium channel blocker	China, Korea and Taiwan
Oldeca (barnidipine hydrochloride)	capsules	sustained release calcium antagonist	Korea

Sales of the Products: approx. ¥5.0 billion (fiscal year ended March 31, 2019)

(5) Outline of the succeeding company

Daiichi Sankyo Co., Ltd. (TSE: 4568)

Headquarters: 3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo

Representative: President and CEO Sunao Manabe

Operations: Research and development, manufacturing and marketing of pharmaceuticals

The impact from this transaction is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2020 announced in April 2019. Since the consideration for the transfer of the Products is recognized as revenue during the current fiscal year, we expect a positive impact on revenue and operating profit.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers

in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473